UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JANUARY 14, 2003
IMMUNOGEN, INC.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-17999 04-2726691
(State or other (Commission (IRS Employer
jurisdiction of incorporation) File Number) Identification No.)
128 SIDNEY STREET, CAMBRIDGE, MA 02139
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 995-2500
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
EXHIBIT NO. EXHIBIT
----------- -------
99.1 Certification of Chief Executive Officer and Chief
Financial Officer
ITEM 9. REGULATION FD DISCLOSURE
In connection with the Amendment to the Quarterly Report on Form 10-Q of
ImmunoGen, Inc. (the "Company") for the quarterly period ended December 31,
2001, as filed with the Securities and Exchange Commission concurrently
herewith, the Company hereby files the written statement required by Section 906
of the Sarbanes-Oxley Act of 2002. On January 14, 2003, Mitchel Sayare, Chief
Executive Officer and President of the Company and Gregg D. Beloff, Chief
Financial Officer and Vice President, Finance of the Company, each executed this
written statement. A copy of the foregoing written statement is attached hereto
as an exhibit and incorporated herein by reference.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMMUNOGEN, INC.
(Registrant)
Date: JANUARY 14, 2003 /s/ GREGG D. BELOFF
-------------------------------------
Gregg D. Beloff
Chief Financial Officer and
Vice President, Finance
3
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
----------- -------
99.1 Certification of Chief Executive Officer and Chief Financial
Officer